January 8, 2025 01:14 PM EST

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Kyle LaHucik

Senior Reporter

Astellas has ended work on a cell therapy that it was exploring for CD20-positive B cell lymphomas, the Japan-based pharma confirmed to Endpoints News …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Astellas stops developing autologous cell therapy using tech from Xyphos buyout

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Global Head of Marketing

Bachem

Bubendorf, BL, Switzerland

Versant unveils Light Horse with $62M and a partnership with Novartis

After lackluster 2024, biopharma industry prays stalled M&A will finally move into gear

Aiolos team reunites with $411M for new biotech with obesity drugs from China

Exclusive: First-of-its-kind infant DNA edit leads to apparent cure in disease that set back field 25 years ago

Cell therapy startup A2 Biotherapeutics nets $80M Series C

Leyden Labs gets $70M to test if nasal sprays can help protect against viruses

Astel­las stops de­vel­op­ing au­tol­o­gous cell ther­a­py us­ing tech from Xyphos buy­out

Senior Reporter

Sign up to read this article for free.

more like this

Bachem

Bubendorf, BL, Switzerland

Astellas stops developing autologous cell therapy using tech from Xyphos buyout